Anthony M. Rossi, MD

Dr. Rossi is a Fellow in Procedural Dermatology and Mohs Surgery, Memorial Sloan-Kettering and Weill Cornell/New York-Presbyterian Hospital, both in New York, New York.

Dr. Rossi reports no conflicts of interest in relation to this post.

In the April 2013 issue of the Journal of Drugs in Dermatology (2013;12:428-431), Clark et al retrospectively reviewed 115 laser sessions with the 1550-nm erbium-doped fractional nonablative laser (Fraxel Re:Store SR 1550, Solta Medical) in 45 patients with Fitzpatrick skin types IV to VI to assess the rate of postinflammatory hyperpigmentation and the associated laser parameters. The fluence, treatment level, and number of passes were all reviewed, as well as any posttreatment complications (ie, erythema, blistering, edema, bruising, pain) and long-term (1 month) complications (ie, hypopigmentation, hyperpigmentation).

Anthony M. Rossi, MD

Dr. Rossi is a Fellow in Procedural Dermatology and Mohs Surgery, Memorial Sloan-Kettering and Weill Cornell/New York-Presbyterian Hospital, both in New York, New York.

Dr. Rossi reports no conflicts of interest in relation to this post.

The September 2012 issue of Dermatologic Surgery (2012;38:1477-1489) featured a randomized controlled trial of 4 different fractionated ablative lasers used in the treatment of facial photoaging. The authors utilized 4 different lasers on 12 participants, with the treatment area being the face (divided into 4 quadrants). The lasers tested included the Fraxel Repair (Solta Medical Inc) fractionated CO₂ 10,600-nm laser, Active and Deep FX (Total FX; Lumenis) fractionated CO₂ 10,600-nm laser, Quadralase (Candela) fractionated CO₂ 10,600-nm laser, and Pearl Fractional (Fx; Cutera) fractionated yttrium-scandium-gallium-garnet (YSGG) 2790-nm laser.